Total metabolic lesion volume of lymph nodes measured by ¹⁸F-FDG PET/CT: a new predictor of macrophage activation syndrome in adult-onset Still’s disease

Abstract

Background

To investigate the potential utility of quantitative parameters obtained by ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) in the assessment of disease severity and the occurrence of macrophage activation syndrome (MAS) in adult-onset Still’s disease (AOSD).

Methods

Fifty-seven patients with AOSD who underwent pre-treatment ¹⁸F-FDG PET/CT were recruited in this study and compared with 60 age- and sex-matched healthy controls. Clinical features and laboratory data were recorded. The systemic score was assessed to determine the disease severity. The maximal standardized uptake value (SUV_max), metabolic lesion volume (MLV), and total lesion glycolysis (TLG) were used to evaluate the involved organs and tissues that abnormally accumulated ¹⁸F-FDG. Multivariate analysis was performed to identify the PET/CT-derived risk factors contributing to the AOSD-related MAS, and their diagnostic efficiency was evaluated.

Results

High ¹⁸F-FDG accumulation was observed in the bone marrow (SUV_max median, 5.10), spleen (SUV_max median, 3.70), and lymph nodes (LNs, SUV_max median, 5.55). The SUV_max of the bone marrow (rho = 0.376, p = 0.004), SUV_max of the spleen (rho = 0.450, p < 0.001), TLG_total of LNs (rho = 0.386, p = 0.017), and MLV_total of LNs (rho = 0.391, p = 0.015) were correlated with the systemic score. The SUV_max of the spleen (p = 0.017), TLG_total of LNs (p = 0.045), and MLV_total of LNs (p = 0.012) were higher in patients with MAS than in those without MAS. A MLV_total of LNs > 62.2 (OR 27.375, p = 0.042) was an independent predictive factor for MAS with a sensitivity of 80.0% and a specificity of 93.9%.

Conclusions

The glucose metabolic level of the spleen could be an effective and easy-to-use imaging indicator of disease severity, and MLV_total of LNs > 62.2 was a strong predictor of MAS occurrence in patients with AOSD.

Introduction

Adult-onset Still’s disease (AOSD) is a systemic inflammatory disease characterized by spiking fever, salmon-pink evanescent rash, arthralgia, and hepatosplenomegaly [1]. The laboratory profile of AOSD is a reflection of systemic inflammation, including increased erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), as well as hyperferritinemia, leukocytosis, and elevated levels of cytokines [2]. Diagnosis of AOSD is based on clinical pattern recognition and exclusion of other autoimmune, inflammatory, infectious, or neoplastic diseases [3–5]. The patients with AOSD may experience life-threatening complications, especially companied with macrophage activation syndrome (MAS), with high mortality rate ranging from 10 to 42.5% [6, 7]. Early recognition and treatment of MAS is crucial but challenging, due to the lack of specific markers [8, 9].

¹⁸F-fluorodesoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT), which reflects both the glucose metabolic activity and the anatomical structure of target tissues, is commonly used on cancer diagnosis, staging, and prognosis, assessment of treatment response [10]. For AOSD, ¹⁸F-FDG PET/CT has been used as a whole-body imaging tool to exclude malignancies and identify the biopsy sites when the patients were at admission [11, 12]. Previous studies (13 cases [13], seven cases [14], and 26 cases [12]) have revealed the significant increase of FDG uptake of involved organs in patients with AOSD. However, the correlations between abnormal glucose metabolism of involved organs, as determined by the maximal standardized uptake value (SUV_max), and disease severity are still illusive.

PET/CT-derived quantitative parameters based on three-dimensional volume of interest (VOI), namely metabolic tumor volume (MTV) and total lesion glycolysis (TLG), have been widely used in the assessment of whole-body disease burden and prognosis of tumors [15, 16]. Interestingly, recent studies presented associations between TLG and systemic inflammation in patients with recurrent colorectal cancer [17] and IgG₄-related disease [18]. Here, we quantified ¹⁸F-FDG uptake in patients with AOSD using SUV, MTV, and TLG, in pursuit of identifying markers associated with disease severity and AOSD-related MAS as well.

Material and methods

Patient recruitment

From November 2015 to January 2019, we identified 57 hospitalized patients diagnosed with AOSD according to the classification criteria proposed by Yamaguchi et al. at an academic hospital [4]. Clinical manifestations and laboratory data were obtained on admission, and a systemic score, as proposed by Pouchot [19], was assessed for each patient. Macrophage activation syndrome (MAS) was diagnosed based on HLH-2004 criteria [20]. All patients underwent ¹⁸F-FDG PET/CT scan for excluding malignancy before treatments of AOSD. In addition, to determine the glucose metabolic level of normal tissues and organs on PET/CT, 60 age- and sex-matched healthy controls without a history of autoimmune disease, recent infection, or malignant tumor were retrospectively recruited. The study was approved by the Ethics Committee of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine.

PET/CT scanning

¹⁸F-FDG PET/CT scanning was performed using the Discovery VCT64 system (GE Healthcare, Chicago, IL, USA). To control the blood glucose concentration below 7.4 mmol/L before scanning, patients were instructed to fast for at least 6 h. Patients received an intravenous injection of 5–6 MBq of ¹⁸F-FDG per kilogram of body weight 45–60 min before scanning from the skull base to the mid-thigh. PET images were acquired for 3 min per bed position using a matrix size of 128 × 128, 28 subsets, two iterations, and full-width half-maximum post-filtering. CT images were acquired using a tube voltage of 140 kV, a tube current of 220 mA, and a section thickness of 3.75 mm. The reconstruction of PET images was based on an ordered-subset expectation maximization algorithm with photon attenuation correction using CT data.

PET/CT image interpretation

Integrated PET and CT images were independently interpreted by two nuclear medicine physicians on the Advantage Workstation 4.4 system (GE Healthcare). The glucose metabolic level of the bone marrow, spleen, liver, and lymph nodes (LNs) in all patients with AOSD were assessed by the SUV_max and SUV_mean within the VOI drawn on the PET/CT images. The abnormal hypermetabolism of these organs and tissues were defined as SUV_max higher than the upper limit of the 95% confidence interval for the glucose metabolic level of them in the healthy controls. LNs with ¹⁸F-FDG uptake lower than blood pool were excluded from analyses. In this study, the MTV was renamed as the metabolic lesion volume (MLV) because AOSD-affected lesions were non-neoplastic. Both the MLV and TLG [18] were measured on all hypermetabolic LNs. The MLV was automatically delineated using a threshold of 40% of the SUV_max. The TLG was defined as the MLV multiplied by the SUV_mean. The total MLV (MLV_total), which summed MTVs, and the total TLG (TLG_total), which summed TLGs, in all hypermetabolic LNs were measured as the quantitative parameters of whole-body disease burden. Because of the irregular shape of the bone marrow and spleen, and the vicinity of the physiologically ¹⁸F-FDG-avid kidney, it was difficult to obtain VOIs completely covering either organ where the MLV and TLG could not be measured.

Statistical analysis

Statistical analysis was performed using SPSS (version 23, IBM Corporation) and R (version 3.6.2) software packages. Chi-square and Fisher’s exact tests were used to compare categorical variables. The Mann-Whitney rank sum test was used to compare continuous variables with non-normal distribution after the Kolmogorov-Smirnov test. The Wilcoxon signed-rank test was used to compare paired continuous variables with non-normal distribution. Spearman’s correlations were analyzed to examine the relationship between PET/CT parameters and laboratory indices with a Bonferroni correction. Binary logistic regression and Firth logistic regression [21] were used to evaluate the contribution of different clinical risk factors to disease severity. All the variables were included in the regression mode. The variables with p < 0.1 in univariate analysis were entered in multivariate analysis. Multicollinearity was excluded from the final model. Receiver operating characteristic curves (ROCs) were performed to determine the diagnostic performance of the PET/CT parameters. The optimum cutoff value was defined based on the maximum Youden index. The diagnostic accuracy of each parameter was reported together with its 95% confidence interval (CI). Statistical significance was defined as p < 0.05.

Results

Clinical information of patients with AOSD

All the information is presented in Table 1. The median age of the 57 patients was 34, with a female predominance of 84.21%. The most prevalent clinical manifestations were arthralgia (91.23%) and skin rash (91.23%), followed by fever higher than 39 °C (80.70%). Increased levels of CRP (94.74%), serum ferritin (87.72%), and ESR (73.68%) were commonly observed. The median systemic score was 7.

Table 1.

Patient characteristics

Demographics
Number	57
Age (y)	34 (26–47)
Female	48/9
Disease duration (months)	3 (1–12)
Clinical features
Fever > 39 °C	46 (80.7)
Skin rash	52 (91.2)
Arthralgia	52 (91.2)
Sore throat	44 (77.2)
Lymphadenopathy	43 (75.4)
Splenomegaly	25 (43.9)
Hepatomegaly	9 (15.8)
Pleuritis	20 (35.1)
Pericarditis	14 (24.6)
Weight loss	14 (24.6)
Lung disease	1 (1.8)
Laboratory findings
Leukocytosis (> 10,000/mm3)	34 (59.7)
Neutrophils (> 80%)	36 (63.2)
Hb < 90 g/L	9 (15.8)
PLT < 100,000/mm3	2 (3.5)
ESR > 40 mm/h	42 (73.7)
CRP > ULN	54 (94.7)
Serum ferritin > 5 ULN	36 (63.2)
Abnormal liver function	36 (63.2)
Negative ANA (titer ≤ 1:80)	54 (94.7)
Negative RF	56 (98.2)
IL2R > ULN	33/45 (73.3)
Pouchot score	7 (5–7.5)

Data are presented in the form of median (Q1–Q3) as continuous variable or as absolute number (percentage of the total patients%);

ULN upper limit of normal, Hb hemoglobin, PLT platelet, ESR erythrocyte sedimentation rate, ANA antinuclear antibody, RF rheumatoid factor, CRP C-reactive protein, IL-2R interleukin-2 receptor

Characterization of abnormal ¹⁸F-FDG accumulation in patients with AOSD

The accumulation of ¹⁸F-FDG was significantly higher in the bone marrow, spleen, and LNs in patients with AOSD than healthy controls, except for ¹⁸F-FDG uptake in the liver (p = 0.672) (Table 2). Representative PET/CT images of abnormal hypermetabolic distributions in two patients with AOSD are depicted in Fig. 1.

Table 2.

¹⁸F-FDG accumulation in the mainly involved organs and tissues in patients with AOSD compared with healthy controls

	N (%)	SUVmax in patients with AOSD	Bilateral (n)	SUVmax in healthy controls	p
Bone marrow	–	5.10 (4.25–6.10)	–	3.76 (3.00–4.15)	< 0.001
Spleen	–	3.70 (3.05–4.35)	–	2.28 (2.06–2.56)	< 0.001
Liver	–	3.20 (2.80–3.60)	–	3.26 (2.88–3.58)	0.672
Lymph nodes#	38 (66.67)	5.55 (4.05–8.68)	–	–	–
Cervical LN	30 (52.63)	5.15 (3.92–7.85)	26/30	–	–
Axillary LN	27 (47.37)	4.70 (2.70–6.00)	25/27	–	–
Mediastinum LN	19 (33.33)	5.30 (3.70–8.90)	–	–	–
Pelvic LN	16 (28.07)	6.45 (4.68–8.52)	–	–	–
Retroperitoneal LN	14 (24.56)	5.60 (3.15–7.72)	–	–	–
Inguinal LN	13 (22.81)	4.20 (2.65–5.20)	10/13	–	–
Abdominal LN	8 (14.04)	6.60 (5.25–7.70)	–	–	–

Data are presented in the form of median (Q1–Q3) as continuous variable

SUV standardized uptake value

^#This was calculated from the patients with hypermetabolic lymph nodes (n = 38). SUVmax was the maximum SUV of the regional lymph node

Fig. 1.

Whole-body PET image (a) and axial hybrid PET/CT images of the axillary LNs (b), liver and spleen (c), and pelvis bone (d) from a 45-year-old female patient with fever, skin rash, and arthralgia showed increased ¹⁸F-FDG uptake by the right axillary LNs (SUV_max, 6.7), spleen (SUV_max, 4.7), liver (SUV_max, 3.3), and pelvic bone marrow (SUV_max, 4.3). The TLG_total of LNs was 199,697.4, and MLV_total of LNs was 53.88. The patient did not progress to MAS after glucocorticoids and methotrexate treatment. Another 42-year-old female patient with fever, skin rash, and lymphadenopathy showed increased ¹⁸F-FDG uptake by the left axillary LNs (SUV_max, 9.8), mediastinum LNs (SUV_max, 11.4), spleen (SUV_max, 7.5), liver (SUV_max, 4.7), and pelvic bone marrow (SUV_max, 5.1) on whole-body PET image (e) and axial hybrid PET/CT images of the axillary and mediastinum LNs (f), liver and spleen (g), and pelvis bone (h). The TLG_total of LNs was 1,144,469.8, and MLV_total of LNs was 244.75. The patient progressed to MAS after glucocorticoid treatment. Lately, she received intravenous immunoglobulins and achieved remission. LNs, lymph nodes; SUV, standardized uptake value; TLG, total lesion glycolysis; MLV, metabolic lesion volume; MAS, macrophage activation syndrome

Bone marrow hypermetabolism occurred in 61.40% (35/57) of the patients, while spleen hypermetabolism occurred in 75.44% (43/57) of the patients. 66.7% (38/57) patients showed hypermetabolic LNs. In these cases, bilateral distribution of hypermetabolic LNs was commonly observed. The most commonly involved superficial LNs were cervical LNs (30/38, 78.95%) and axillary LNs (27/38, 71.05%), followed by inguinal LNs (13/38, 34.21%). Deep hypermetabolic LNs were also frequently observed, ranking with mediastinum LNs (19/38, 50.00%), pelvic LNs (16/38, 42.11%), retroperitoneal LNs (14/38, 36.84%), and abdominal LNs (8/38, 21.05%). In addition, four patients exhibited hypermetabolic LNs at the unilateral upper arm (intra-muscle).

Because of the limited scan range of PET/CT in this study, only the hip and shoulder joints were evaluated. Increased ¹⁸F-FDG uptake by the hip joints was only seen in one patient, with a SUV_max of 3.1, whereas three patients showed hypermetabolic shoulder joints with SUV_max of 3.1–3.3.

Abnormal FDG uptake by the right subscapularis was observed in only one patient. There was no increased ¹⁸F-FDG uptake by the skin in our cohort. In addition, there was only one (1.75%) patient in our cohort who showed parenchymal lung involvement with a SUV_max of 2.2 on the lung.

Correlations between laboratory findings, systemic score, and PET/CT parameters

The correlations between disease severity-related laboratory findings and PET/CT parameters are summarized in Table S1. The spleen hypermetabolism showed positive correlations with ferritin (rho = 0.478, p < 0.001), lactate dehydrogenase (LDH) (rho = 0.462, p < 0.001), and interleukin-2 receptor (IL-2R) (rho = 0.454, p = 0.002). The SUV_max of the LN negatively correlated with the white blood cell count (rho = − 0.500, p = 0.001). The MLV_total of LNs displayed a positive correlation with the levels of IL-2R (rho = 0.495, p = 0.004).

The systemic score is a widely used indicator of AOSD disease severity. The SUV_max of the spleen (rho = 0.450, p < 0.001), SUV_max of the bone marrow (rho = 0.376, p = 0.004), TLG_total (rho = 0.386, p = 0.017), and MLV_total (rho = 0.391, p = 0.015) of LNs showed significant correlations with the systemic score (Fig. 2). Notably, the patients with systemic score ≥ 7 showed significantly higher SUV_max of the bone marrow (p = 0.005), spleen (p = 0.002), TLG_total (p = 0.044), and MLV_total (p = 0.033) of LNs than those with systemic score < 7 (Table S2).

Fig. 2.

Correlations between the SUV_max of the bone marrow (a), spleen (b), liver (c), LNs (d), TLG_total (e), MLV_total, (f) of LNs, and the systemic score. SUV, standardized uptake value; TLG, total lesion glycolysis; MLV, metabolic lesion volume. Significance was set at p < 0.05

PET/CT features in MAS

Eight of 57 patients were diagnosed with MAS during the current hospitalization and underwent PET/CT scanning before the diagnosis of MAS. The time interval between PET/CT scanning and the diagnosis of MAS ranged from 2 to 33 days (Table S3). Only two patients showed cytopenia involving cells of 1 lineage, suggesting MAS might be in development when performing PET/CT.

Patients with MAS showed significantly higher SUV_max of the spleen (p = 0.017, n = 8), TLG_total (p = 0.045, n = 5), and MLV_total of LNs (p = 0.012, n = 5) compared to patients without MAS (Table 3). Considering the high mortality rate of MAS, the risk factors for MAS were assessed (Table 4). ROC analyses revealed that MLV_total of LNs > 62.2, SUV_max of the spleen > 3.55, and TLG_total of LNs > 248,040 were the optimal cut-points for discriminating MAS occurrence. Elevated levels of LDH, IL-2R, platelet count, TLG_total of LNs > 248,040, SUV_max of the spleen > 3.55, and MLV_total of LNs > 62.2 significantly associated with MAS occurrence in univariate analysis. Subsequent multivariate analyses indicated that elevated IL-2R level and MLV_total of LNs > 62.2 were independent risk factors of MAS.

Table 3.

Comparison of PET/CT parameters between the patients with and without MAS

	Patients with MAS	Patients without MAS	p
	n = 8	n = 49
SUVmax of the bone marrow	4.95 (3.68–5.40)	5.50 (4.30–6.15)	0.214
SUVmax of the spleen	4.35 (3.78–5.75)	3.50 (3.00–4.10)	0.017
SUVmax of the liver	3.10 (2.85–3.65)	3.30 (2.75–3.60)	0.854
SUVmax of LNs	7.30 (4.65–11.80)	5.20 (4.00–8.00)	0.271
TLGtotal of LNs	261,170.20 (86,548.35–851,990.60)	44,518.30 (8828.20–159,463.70)	0.045
MLVtotal of LNs	87.81 (38.78–189.47)	20.05 (4.74–46.12)	0.012

Data are presented in the form of median (Q1–Q3) as continuous variable

Table 4.

Risk factors for the occurrence of MAS

	Univariate analysis			Multivariate analysis
	p	OR	95% CI	p	OR	95% CI
Age	0.138	0.955	0.898–1.015
Sex	0.784	1.366	0.147–12.677
LDH	0.009	1.005	1.001–1.008
PLT	0.035	0.992	0.984–0.999
IL-2R	0.002	1.002	1.001–1.003	0.002	1.003	1.001–1.007
SUVmax of the spleen > 3.55	0.004	19.170	2.182–2528.558
TLGtotal of LNs > 248,040	0.013	15.000	1.752–128.391
MLVtotal of LNs > 62.2	0.002	62.000	4.529–848.704	0.042	27.375	1.117–123,080.200

Both TLG_total and MLV_total of LNs were calculated from the patients with hypermetabolic lymph nodes (n = 38). All laboratory variables were included in logistic regression, and only the results with p < 0.1 were listed here

LDH lactate dehydrogenase, PLT platelet, IL-2R interleukin-2 receptor, SUV standardized uptake value, LN lymph node, TLG total lesion glycolysis, MLV metabolic lesion volume, MAS macrophage activation syndrome

MLV_total of LNs > 62.2 had a sensitivity of 80.0%, a specificity of 93.9%, and an AUC of 0.855 in predicting MAS occurrence, which were comparable with those of the traditional marker, IL-2R (sensitivity, 75.0%; specificity, 97.3%; AUC, 0.899). Level of ferritin, SUV_max of the spleen, and the systemic score showed low specificity of 40.8–55.1% and AUC of 0.642–0.765 (Table 5).

Table 5.

The AUC, sensitivity, specificity, and likelihood ratio of PET/CT parameters, serologic markers, and systemic scoring for predicting the occurrence of MAS

Factor	AUC (95% CI)	Cutoff value	Sensitivity, % (95% CI)	Specificity, % (95% CI)	Likelihood ratio
IL-2R	0.899 (0.776–0.999)	2824 pg/ml	75.0 (40.9–95.6)	97.3 (48.7–99.9)	27.8
MLVtotal of LNs	0.855 (0.642–0.999)	62.2	80.0 (37.6–99.0)	93.9 (80.4–98.9)	13.2
SUVmax of the spleen	0.765 (0.630–0.900)	3.55	100.0 (67.6–100.0)	53.1 (39.4–66.3)	2.13
Systemic score ≥ 7	0.713 (0.541–0.885)		87.5 (52.9–99.4)	55.1 (41.3–68.1)	1.95
Ferritin > 5 ULN	0.642 (0.455–0.828)		87.5 (52.9–99.4)	40.8 (28.2–54.8)	1.48

LN lymph node, MLV metabolic lesion volume, IL-2R interleukin-2 receptor, MAS macrophage activation syndrome. MLV_total of LNs were calculated from the patients with hypermetabolic lymph nodes (n = 38)

Discussion

¹⁸F-FDG PET/CT is a useful tool to rule out malignancy before the diagnosis of AOSD. The additional values including the potential correlations between the PET/CT findings and disease assessments are worth to be investigated. Hypermetabolic status of the bone marrow, spleen, and LNs in patients with AOSD have been observed in other studies [11–14, 22–25]. We further explored the utility of PET/CT to assess disease severity and MAS occurrence of AOSD. Our study suggests that PET/CT could act as an early detective tool to evaluate the disease severity and predict the occurrence of deadly complication, MAS, in patients with AOSD.

The glucose metabolic level of the spleen could be an effective indicator of AOSD severity. In the present study, not only positive correlations between SUV_max of the spleen and those laboratory profiles of AOSD including the levels of LDH, ferritin, and IL-2R were observed, but also the hypermetabolism of the spleen showed a higher correlation coefficient with systemic score and more frequent occurrence in patients with AOSD than those of the bone marrow and LNs. We assumed that the enhanced FDG accumulation in the spleen may be secondary to inflammation and hypercytokinemia [26]. Furthermore, compared to the bone marrow and LNs, the spleen as a morphologically oblate and single organ is more likely to be drawn in a VOI on PET/CT images for more reliably and easily measuring its glucose metabolic levels in clinical practice. Additionally, a negative correlation between SUV_max of LNs and the white blood cell count was observed, which might be due to virus infection which was known as a trigger to AOSD [27–29], thereby temporarily disrupting the homeostasis of the bone marrow [30]. Although both elevated [24] and reduced [31] ¹⁸F-FDG uptake of the liver was observed in previous case reports, there was no statistical difference of SUV_max of the liver between patients with AOSD and healthy controls in our study. Similar to the studies of Dong et al. [12] and Jiang et al. [11], the prevalence of articular involvement in our cohort (10.53%) was low, indicating that increased ¹⁸F-FDG uptake in the joints may not be significant in patients with AOSD, which was probably due to the relatively mild involvement of joints in Chinese patients [32].

MLV_total of LNs was a promising useful predictor of MAS occurrence in patients with AOSD. Previous studies have reported that ¹⁸F-FDG PET/CT-derived quantitative parameters were associated with the occurrence [33] or outcome of MAS [34, 35]. In our study, we further found that MLV_total of LNs had better diagnostic performance than SUV_max of the spleen and TLG_total of LNs for distinguishing patients with MAS from those without MAS. Hypermetabolism of whole-body LNs is believed to be due to the high accumulation of inflammatory cells and the over-activation of the mononuclear phagocyte system in LNs [34, 36]. Patients with MLV_total of LNs > 62.2 showed a 20-fold increased risk for MAS occurrence than those with MLV_total of LNs less than or equal to 62.2. IL-2R may serve as a good laboratory indicator of MAS [37]. In this study, the IL-2R level was also an independent factor for predicting MAS occurrence with comparably high likelihood ratios to MLV_total of LNs. Even if the predictive value of IL-2R, as a cheaper test than PET/CT, was already high, the value of PET/CT was not negligible. Firstly, the performance of IL-2R for diagnosing MAS is still limited [38, 39], especially with low specificity (38.8–72.5%). Secondly, PET/CT has been routinely used to rule out malignancy in the diagnosis of AOSD. Its evaluation of the MAS occurrence could bring additional diagnostic information to clinicians. We believe that the combined diagnosis of IL-2R and MLV_total of LNs may have better predictive performance for MAS, but this conclusion cannot be obtained due to the limited number of samples in the present study. Therefore, further attention should be given to the whole-body inflammatory burden reflected by the MLV_total of LNs for assessing the risk of MAS in patients with AOSD. Recently, the negative prognostic impact of lung involvement in patients with AOSD has been reported [40], and the lung involvement has been correlated with the occurrence of MAS [41, 42]. However, due to the low prevalence of parenchymal lung involvement in our study, no inferential analysis was made.

There are still some limitations in this study. (a) The number of cases with MAS was low (n = 8) leading to the possibility of model overfitting. (b) Short-term glucocorticoid treatment before PET/CT scanning in some patients may have a limited effect on the accuracy of SUV measurement [43]. (c) There was a short time interval between PET/CT and diagnosis of MAS in two patients, whereas other six patients were diagnosed with MAS 1 week after PET/CT scan. Therefore, PET/CT may act as an actual display of the current disease activity as well as a prediction over time. This study was a pilot study at a single center, and more high evidence studies are needed to verify the reliability of the PET/CT parameters in the assessment of disease severity and the prediction of MAS in patients with AOSD.

Conclusions

Our data revealed that the glucose metabolic level of the spleen could be an effective and easy-to-use imaging indicator of disease severity, and MLV_total of LNs > 62.2 was a strong predictor of MAS occurrence in patients with AOSD.

Abbreviations

¹⁸F-FDG PET/CT

¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography

AOSD

Adult-onset Still’s disease

AUC

Area under the curve

CI

Confidence interval

CRP

C-reactive protein

csDMARDs

Conventional synthetic disease-modifying anti-rheumatic drugs

CT

Computer tomography

ESR

Erythrocyte sedimentation rate

IL

Interleukin

LNs

Lymph nodes

MAS

Macrophage activation syndrome

MLV_total

Total metabolic lesion volume

MRI

Magnetic resonance imaging

VOI

Volume of interest

MTX

Methotrexate

NSAIDs

Nonsteroidal anti-inflammatory drugs

SUV_max

Maximal standardized uptake value

MTV

Metabolic tumor volume

TLG

Total lesion glycolysis

TNF

Tumor necrosis factor

TLG_total

Total lesion glycolysis

ROC

Receiver operating characteristic curve

Authors’ contributions

MZ, HS, and CD Y designed the project and supervised the project. HH C, ZH W, QY H, CD Y, H S, JC J, LY W, and JY G collected the clinical data. MZ and YT G read the scans. LY W and JY G analyzed the data and performed statistical analyses. LY W, JY G, and TT L wrote the manuscript with contributions from all authors. The authors read and approved the final manuscript.

Funding

This work was supported by grants from Shanghai Jiao Tong University Medicine and Engineering Interdisciplinary Funding (YG2017MS61, YG2017QN58, and ZH2018QNA47), Shanghai Municipal Key Clinical Specialty (shslczdzk03403), and Shanghai Pujiang Program (18PJD030).

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Declarations

Ethics approval and consent to participate

The study was approved by the Ethics Committee of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. As a retrospective study, this study was exempt from informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Supplementary information

Supplementary information accompanies this paper at 10.1186/s13075-021-02482-2.